TPG GP A’s Allogene Therapeutics ALLO Stock Holding History

TPG GP A’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.9M	Hold	18,716,306	–	–	0.78%	20
2026 Q1	$45.7M	Hold	18,716,306	–	–	1.24%	15
2025 Q4	$25.6M	Hold	18,716,306	–	–	0.95%	8
2025 Q3	$23.2M	Hold	18,716,306	–	–	1.26%	7
2025 Q2	$21.1M	Hold	18,716,306	–	–	1.13%	8
2025 Q1	$27.3M	Hold	18,716,306	–	–	0.54%	27
2024 Q4	$39.9M	Hold	18,716,306	–	–	0.64%	29
2024 Q3	$52.4M	Hold	18,716,306	–	–	0.89%	23
2024 Q2	$43.6M	Hold	18,716,306	–	–	0.68%	27
2024 Q1	$83.7M	Hold	18,716,306	–	–	1.6%	18
2023 Q4	$60.1M	Hold	18,716,306	–	–	0.97%	26
2023 Q3	$59.3M	Hold	18,716,306	–	–	1.02%	23
2023 Q2	$93M	Hold	18,716,306	–	–	1.37%	19
2023 Q1	$92.5M	Hold	18,716,306	–	–	1.51%	19
2022 Q4	$118M	Hold	18,716,306	–	–	2.31%	16
2022 Q3	$202M	Hold	18,716,306	–	–	3.31%	12
2022 Q2	$213M	Hold	18,716,306	–	–	3.3%	11
2022 Q1	$171M	Hold	18,716,306	–	–	2.11%	14
2021 Q4	$279M	Buy	+18,716,306	New	+$330M	2.79%	10

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TPG GP A's ALLO Position: Q2 2026 in Review

TPG GP A held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 18,716,306 shares worth $38.9M. The position accounts for 0.78% of the portfolio, ranked #20.

TPG GP A first reported a position in ALLO in Q4 2021 and has held it in 19 quarters since. The position peaked at $279M in Q4 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

TPG GP A held 18,716,306 shares of Allogene Therapeutics worth $38.9M as of Q2 2026.
TPG GP A left its Allogene Therapeutics share count unchanged in Q2 2026.
Allogene Therapeutics made up 0.78% of TPG GP A's portfolio in Q2 2026, its #20 holding.
TPG GP A first reported a position in Allogene Therapeutics in Q4 2021 and has held it in 19 quarters since.
TPG GP A's Allogene Therapeutics position peaked at $279M in Q4 2021.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on TPG GP A's 13F filing for Q2 2026, filed 14 Aug 2026.